The Down-Shifting Luminescence of Rare-Earth Nanoparticles for Multimodal Imaging and Photothermal Therapy of Breast Cancer.
Tingting GaoSiqi GaoYaling LiRuijing ZhangHonglin DongPublished in: Biology (2024)
Nanotheranostic agents capable of simultaneously enabling real-time tracking and precise treatment at tumor sites play an increasingly pivotal role in the field of medicine. In this article, we report a novel near-infrared-II window (NIR-II) emitting downconversion rare-earth nanoparticles (RENPs) to improve image-guided therapy for breast cancer. The developed α-NaErF4@NaYF4 nanoparticles (α-Er NPs) have a diameter of approximately 24.1 nm and exhibit superior biocompatibility and negligible toxicity. RENPs exhibit superior imaging quality and photothermal conversion efficiency in the NIR-II range compared to clinically approved indocyanine green (ICG). Under 808 nm laser irradiation, the α-Er NPs achieve significant tumor imaging performance and photothermal effects in vivo in a mouse model of breast cancer. Simultaneously, it combines X-ray computed tomography (CT) and ultrasound (US) tri-modal imaging to guide therapy for cancer. The integration of NIR-II imaging technology and RENPs establishes a promising foundation for future medical applications.
Keyphrases
- high resolution
- photodynamic therapy
- fluorescence imaging
- computed tomography
- drug release
- magnetic resonance imaging
- mouse model
- positron emission tomography
- healthcare
- drug delivery
- oxidative stress
- radiation therapy
- quantum dots
- magnetic resonance
- endoplasmic reticulum
- quality improvement
- papillary thyroid
- replacement therapy
- breast cancer cells
- light emitting